US OptionsDetailed Quotes
FULC240816C7000
- 1.59
- 0.000.00%
15min DelayClose Jul 23 16:00 ET
0.00High0.00Low
1.59Open1.59Pre Close0 Volume23 Open Interest7.00Strike Price0.00Turnover0.00%IV-2.83%PremiumAug 16, 2024Expiry Date1.84Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.56Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Fulcrum Therapeutics Stock Discussion
Sign in to post a comment
$Fulcrum Therapeutics(FULC.US$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.
1
2
$Fulcrum Therapeutics(FULC.US$ Oh come on what are you waiting for we all know we goin up
$Fulcrum Therapeutics(FULC.US$ Long term looking for dollar 15 range, possible 17 price target to hit. 13.7 resistance 10.4 Fulcrum
5
$Fulcrum Therapeutics(FULC.US$ Fulcrum Therapeutics Inc: Fulcrum Will Receive an Upfront Payment of $80.0 Mln
1
4
$Fulcrum Therapeutics(FULC.US$ Reuters· 2 mins ago
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
2
$Fulcrum Therapeutics(FULC.US$
NEWS
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024.
P...
NEWS
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024.
P...
2
$Fulcrum Therapeutics(FULC.US$ 👀 not bad ! valid float, price retest 12.14 setting me buy alert to head target 16.50
Fulcrum Therapeutics' falling operating revenue and significant cash burn relative to market value pose risks, despite a 13% cut in cash burn last year. The promising cash runway should be assessed against possible future fundraising costs.
$Fulcrum Therapeutics(FULC.US$ Therapeutics Now Expects That Its Existing Cash And Equivalents To Be Sufficient To Fund Its Operating Requirements Into 2026, An Update To Prior Guidance Of Mid-2025![]()
No comment yet
JESSE JAMES8832 : might be something
TrytosaveabitOP JESSE JAMES8832: Yup! I will be looking to see where it starts to consolidate over the next couple weeks. Then start scaling in!